Brief: Phathom Pharmaceuticals Says FDA Approves Co's Petition For 10 Years Exclusivity For Voquezna
06/06/2025 18:02
June 6 (Reuters) - Phathom Pharmaceuticals Inc PHAT.O: PHATHOM PHARMACEUTICALS ANNOUNCES POSITIVE FDA DECISION TO RECOGNIZE 10 YEARS OF REGULATORY EXCLUSIVITY FOR VOQUEZNA® (VONOPRAZAN) TABLETS THROUGH MAY 3, 2032 ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phathom Pharmaceuticals
See all newsBrief: Phathom Pharma Provides Update On Litigation Filed By BDR Pharma Against FDA
Phathom Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growth
Brief: Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million
Phathom Pharmaceuticals Q1 revenue more than doubles, beats estimates